The retail entitlement offer, which is fully underwritten by Bell Potter Solutions Limited, closed on May 6, 2019 and together with shares issued under the institutional component of the entitlement offer, the total amount raised will be about $26.3 million.
READ: Paradigm Biopharmaceuticals completes institutional component of $26.3 million entitlement offer
The shortfall under the entitlement offer will rank equally with existing shares on issue.
Shares issues under the retail entitlement offer are expected to be issued on May 13, 2019 and will be allotted and quoted on the ASX on May 14, 2019.
Last Month Paradigm completed the institutional component of the fully underwritten accelerated non-renounceable entitlement offer raising about $9.8 million.
The new funds will allow the company to advance its pivotal phase 3 OA clinical trial in the US, EU and Australia as well as to complete the phase 2/3 pivotal clinical trial in MPS.